Henry Li

Biography

 Henry QX Li, Ph.D. leads CrownBio's Biomarker and Diagnostic Technologies Division, developing novel proprietary translational technologies for precise cancer diagnosis, predictive biomarker discovery, immuno-oncology biomarker detection and quantification, as well as rare cell identification and characterization. Prior to this, Dr. Li has led CrownBio’s Patient-Derived Xenograft (PDX) based translational oncology platform (2011-2016) when he joined Crown. Before joining CrownBio, Dr. Li has over 20 years of biopharmaceutical, as well as academic R&D, experience in cancer and viral infection, including leadership roles as R&D Director/Senior Director in several US-based biotech companies. Dr. Li currently holds visiting Professor position at Peking University-State Key Laboratory. Dr. Li earned his Ph.D. in Molecular Biology/Biochemistry from the University of California (Irvine) and completed his postdoctoral training at UCLA School of Medicine. He has published more than 60 manuscripts and edited 3 books in the biopharmaceutical areas. He is also on the editorial board of Current Signal Transduction Therapy.

Research Interest

 Dr. Li earned his Ph.D. in Molecular Biology/Biochemistry from the University of California (Irvine) and completed his postdoctoral training at UCLA School of Medicine. He has published more than 60 manuscripts and edited 3 books in the biopharmaceutical areas. He is also on the editorial board of Current Signal Transduction Therapy.